Lundbeck Launches Fourth Annual Build Hope for Huntington’s Disease Campaign in Partnership With the Hereditary Disease

  Lundbeck Launches Fourth Annual Build Hope for Huntington’s Disease Campaign
  in Partnership With the Hereditary Disease Foundation

 Campaign helps support a clinic vital to the Huntington’s disease community
                             and genetic research

Business Wire

DEERFIELD, Ill. -- November 12, 2013

Today, Lundbeck and the Hereditary Disease Foundation announced the launch of
the fourth annual Build Hope for HD initiative. The online donation campaign
helps generate support for the Casa Hogar Corea de Huntington Amor y Fe
(Huntington’s Chorea Home of Love and Faith), a unique Venezuelan clinic
serving the families who made possible groundbreaking discoveries in
Huntington’s disease (HD) and other genetic diseases. To trigger a donation
from Lundbeck to help keep this vital clinic open, visit
www.BuildHopeforHD.com or www.hdfoundation.org and click on the campaign icon
before the end of the year. For every click, Lundbeck will donate $15 to the
clinic, up to $25,000.

The Build Hope for HD campaign celebrates an especially important milestone
for the HD community this year. Thirty years ago, scientists supported by the
Hereditary Disease Foundation successfully discovered the location of the HD
gene using DNA markers.^1 This was the first time scientists used DNA markers
to discover any gene. Ten years later, the Gene Hunters – 100 brilliant
scientists supported by the Hereditary Disease Foundation – discovered the HD
gene itself.^2

A group of families living along the shores of Lake Maracaibo, Venezuela, were
critical to these groundbreaking scientific breakthroughs. It is because of
their generosity and collaboration that the HD marker and gene were found.

“Thanks to the families living around the shores of Lake Maracaibo, we were
able to locate the HD gene in 1983 and find the gene itself in 1993,”^1,2 said
Nancy Wexler, Ph.D., President of the Hereditary Disease Foundation and
Higgins Professor of Neuropsychology, Columbia University. “These
extraordinary family members helped revolutionize HD research and forever
change the lives of people living with HD around the world. The Casa Hogar was
opened to pay tribute to the sacrifices made by these families and is a model
for best care practices. It is so important that we continue to support this
community and work together to continue research to find a cure for HD that is
within our grasp. Your support can help make the next discovery possible.”

With support from the Hereditary Disease Foundation, the Casa Hogar clinic was
opened in 1999 after a decade of working with local Venezuelan authorities.
The Casa Hogar provides free general and HD-specific medical treatments, food,
care and an integrated nursing home to thousands of family members with HD who
live along the shores of Lake Maracaibo. The clinic continues to be an
important part of the HD community, serving as a model for patient care,
despite extreme challenges of poverty. The clinic also may serve as a home for
genetic and neurological research that may impact the future of HD
discoveries.

Lundbeck’s annual Build Hope campaign has raised more than $235,000 since its
launch three years ago, allowing the clinic to continue serving the local HD
community.

“HD is a devastating condition that affects about 30,000 people in the United
States alone,”^3 said Arvind Sreedharan, Director of Movement Disorders
Marketing of Lundbeck in the United States. “We are proud to support the Casa
Hogar, and we remain inspired by the contributions of the Venezuelan HD
families and the continued dedication of the researchers working towards
advancements in HD and genetic diseases like it. We look forward to continuing
to work with the HD community, including scientists, clinicians, patients and
their families, as we tread forward in the hopes of further understanding HD.”

To learn more about the clinic and how much each click matters, visit the
Moving Together for HD  Facebook page or the Hereditary Disease Foundation’s
website (www.hdfoundation.org).

About Huntington’s Disease

Huntington’s disease is a hereditary neurodegenerative disease characterized
by a triad of behavioral, cognitive and motor symptoms.^4 These symptoms vary
from person to person. The duration of the disease after the onset of symptoms
can range from 10 to 30 years^5 and currently there is no cure.^5 The HD gene,
whose mutation results in the disease, was localized in 1983 and isolated in
1993.^1,2 For more information on HD, please visit the Hereditary Disease
Foundation website (www.hdfoundation.org).

About the Hereditary Disease Foundation

The Hereditary Disease Foundation aims to cure Huntington’s disease (HD) by
supporting research aimed at developing new treatments and cures. The
Hereditary Disease Foundation was started by Dr. Milton Wexler in 1968 when
his wife was diagnosed with Huntington's disease. The Foundation uses a
variety of strategies – workshops, grants, fellowships, and targeted research
contracts – to solve the mysteries of genetic disease and develop new
treatments and cures. The Hereditary Disease Foundation initiated the
International-Venezuela Huntington’s Disease Collaborative Research Project
and played a key role in the discovery of the HD gene, which was localized in
1983 and isolated in 1993.^1,2 For more information, visit the Hereditary
Disease Foundation website (www.hdfoundation.org).

About Lundbeck in the U.S.

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned
subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is dedicated to providing
innovative specialty therapies that fulfill unmet medical needs of people with
brain disorders, such as Huntington’s disease (HD). In 2010, Lundbeck
initiated the HD Research Initiative to identify and ultimately commercialize
therapies that may slow or halt the progression of HD. This research is driven
by collaborations with academic institutions and companies with promising
compounds in development. For more information, visit www.lundbeckus.com.

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in brain diseases. For more than 50 years, we have been at the
forefront of research within neuroscience. Our development and distribution of
pioneering treatments continues to make a difference to people living with
brain diseases. Our key areas of focus are alcohol dependence, Alzheimer’s
disease, depression/anxiety, epilepsy, Huntington’s disease, Parkinson’s
disease, schizophrenia and stroke. Lundbeck’s U.S. business is based in
Deerfield, Illinois. To learn more about Lundbeck in the U.S., visit
www.lundbeckus.com.

Our 5,800 employees in 57 countries are engaged in the entire value chain
throughout research, development, production, marketing and sales, and are
committed to improving the quality of life of people living with brain
diseases. Our pipeline consists of several late-stage development programs and
our products are available in more than 100 countries. We have research
centers in China, Denmark and the United States, and production facilities in
China, Denmark, France, Italy and Mexico. Lundbeck generated revenue of
approximately DKK15 billion in 2012 (EUR 2 billion; USD 2.6 billion).

Lundbeck’s shares are listed on the stock exchange in Copenhagen under the
symbol “LUN.” Lundbeck has a sponsored Level 1 ADR program listed in the US
(OTC) under the symbol “HLUYY.” For additional information, we encourage you
to visit our corporate site www.lundbeck.com.

References

1. Gusella J, Wexler N, Conneally PM, Naylor S, Anderson M, Tanzi R, Watkins
PC, Ottina K, Wallace M, Sakguchi A, Young AB, Shoulson I, Bonilla E, Martin
JB. A polymorphic DNA marker genetically linked to Huntington’s disease.
Nature 1983; 306:234-238.

2. Huntington’s Disease Collaborative Research Group. A novel gene containing
a trinucleotide repeat that is expanded and unstable on Huntington’s disease
chromosomes. Cell 1993; 72:971-983.

3. Fast Facts About HD. HDSA.org.
http://www.hdsa.org/images/content/1/3/13699.pdf. Last accessed 10/1/13.

4. Marshall FJ, Clinical Features and Treatment of Huntington’s Disease.
Movement Disorders 2004; 1:589-596.

5. Huntington’s Disease. Mayo Clinic.
http://www.mayoclinic.com/health/huntingtons-disease/DS00401/METHOD=print.
Last accessed 10/9/13.

UBR-C-00028

Contact:

for Lundbeck
Rachel Vann, 847-282-1139
 
Press spacebar to pause and continue. Press esc to stop.